analog ⑀-aminocaproic acid (⑀ACA) ( Figure 1D ). In con-3584 CX Utrecht trast, ⑀ACA inhibits the binding of tPA to FP13 by only The Netherlands about 40%, indicating that this interaction is largely lysine independent ( Figure 1D ).
Summary

Fibrin-Derived Peptides Form Cross-␤ Sheets Tissue-type plasminogen activator (tPA) regulates fi-
The above experiments show that the binding of tPA brin clot lysis by stimulating the conversion of plasminto the two peptides occurs through distinct types of ogen into the active protease plasmin [1]. Fibrin is interaction, one supporting tPA-mediated plasminogen required for efficient tPA-mediated plasmin generaactivation, the other not. We considered the possibility tion and thereby stimulates its own proteolysis. Sevthat differences in the peptide structure could underlie eral fibrin regions can bind to tPA [1], but the structural the difference in cofactor activity. The relative contribubasis for this interaction is unknown. Amyloid ␤ (A␤) tion of random coils, ␤ sheets, and ␣ helices to the is a peptide aggregate that is associated with neurostructure of the peptides in solution was studied via toxicity in brains afflicted with Alzheimer's disease [2] . circular-dichroism measurements. Strikingly, we found Like fibrin, it stimulates tPA-mediated plasmin formathat FP13 was in a 100% ␤ sheet conformation with a tion [3-5]. Intermolecular stacking of peptide backcharacteristic minimum at 215 nm and a maximum at bones in ␤ sheet conformation underlies cross-␤ 190 nm (Figure 2A ). In contrast, FP10 was completely structure in amyloid peptides [6] . We show here that randomly coiled, with a minimum observed at 198 nm fibrin-derived peptides adopt cross-␤ structure and (Figure 2A ). Therefore, it seems likely that structural difform amyloid fibers. This correlates with tPA binding ferences underlie the differences in the ability of these and stimulation of tPA-mediated plasminogen activapeptides to activate tPA.
tion. Prototype amyloid peptides, including A␤ and
Given the high ␤ sheet content in FP13 and given islet amyloid polypeptide (IAPP) (associated with panthe finding that amyloid ␤ (A␤) supports plasminogen creatic ␤ cell toxicity in type II diabetes [7] ), have no activation by tPA [3-5], we tested whether FP13 is an sequence similarity to the fibrin peptides but also bind amyloid peptide with cross-␤ sheet conformation. to tPA and can substitute for fibrin in plasminogen Congo Red binds to amyloid peptide aggregates, irreactivation by tPA. Moreover, the induction of cross-␤ spective of the amino acid sequence [8]. Dried samples structure in an otherwise globular protein (endostatin) of FP10 and FP13 were stained with Congo Red and endows it with tPA-activating potential. Our results examined by light microscopy. Figure 2B shows that classify tPA as a multiligand receptor and show that FP13 dried as aggregates that readily bound Congo cross-␤ structure is the common denominator in tPA Red; it displays the characteristic green birefringence binding ligands. Thus, FP13 is an amyloid peptide with cross-␤ sheet conformation, it binds to tPA, and it stimulates tPAmediated plasminogen activation. In contrast, FP10 is in a random-coil conformation and binds to tPA through its C-terminal lysine residue without stimulating tPAmediated plasmin formation. Figure 3A shows that tPA binds to A␤ with high affinity (6.7 nM), as it does to the fibrin peptides. Human islet amyloid polypeptide (hIAPP) is a 37 amino acid peptide that has amyloidogenic properties and is found deposited in the islets of Langerhans in the pancreas of type II diabetic patients. It acts as a diabetogenic factor, presumably by being mice, in contrast to diabetic humans, do not develop tion, albeit less efficiently than the full-length IAPP, whereas cmIAPP was ineffective. When these results pancreatic amyloid deposits because mouse IAPP (mIAPP) has a different amino-acid sequence in this are taken together with the data on the fibrin peptides, we have shown that four amyloid peptides (FP13, A␤, region and lacks the propensity to adopt cross-␤ structure. We tested the presence of cross-␤ structure in hIAPP, chIAPP) stimulate tPA-mediated plasmin formation, whereas two non-amyloid peptides (FP10, cmIAPP) these "core" regions in human and mouse IAPP (chIAPP, cmIAPP) by Congo Red binding and compared their do not. Therefore, the results strongly suggest that tPA binding and cofactor activity require the presence of ability to stimulate tPA-mediated plasminogen activation. As expected, Congo Red readily bound chIAPP, cross-␤ structure in the peptides. How do cross-␤ peptides cause enhanced plasminobut not cmIAPP; it showed green birefringence under polarized light (our unpublished data). Figure 3D shows gen activation? Like fibrin, they could act as scaffolds by promoting the interaction between enzyme (tPA) and that chIAPP stimulated tPA-mediated plasmin forma- Figure 4B shows that endostatin with cross-␤ structure potently stimulates tPA-mediated plasmino-3E shows that the stimulatory effect of the cross-␤ peptides on plasmin generation is lost with increasing congen activation like all the other cross-␤ peptides but that globular endostatin has no effect. Thus, the correlation centrations of tPA. Next, we tested whether the cross-␤ peptides would stimulate tPA enzymatic activity. . This type of interaction within the fibrin meshwork is similar cross-␤ structure and to aggregate into amyloid depos-
